Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer

被引：0

作者：

Panasci, LC ^{[1
]}

机构：

[1] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 15期

关键词：

D O I：

10.1200/JCO.2006.05.7562

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2392 / 2392

页数：1

共 50 条

[41] DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
Inko Nimmrich
Anieta M. Sieuwerts
Marion E. Meijer-van Gelder
Ina Schwope
Joan Bolt-de Vries
Nadia Harbeck
Thomas Koenig
Oliver Hartmann
Antje Kluth
Dimo Dietrich
Viktor Magdolen
Henk Portengen
Maxime P. Look
Jan G. M. Klijn
Ralf Lesche
Manfred Schmitt
Sabine Maier
John A. Foekens
John W. M. Martens
Breast Cancer Research and Treatment, 2008, 111 : 429 - 437
[42] Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage
Yang Yu-qing
Wang Lei
Huang Mei-ling
Xiao Jing-jing
Wei Mei-chen
Wu Jiang
Hao Jun-sheng
Ling Rui
Li Nan-lin
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 150 - 155
[43] DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
Nimmrich, Inko
Sieuwerts, Anieta M.
Gelder, Marion E. Meijer-van
Schwope, Ina
Vries, Joan Bolt-de
Harbeck, Nadia
Koenig, Thomas
Hartmann, Oliver
Kluth, Antje
Dietrich, Dimo
Magdolen, Viktor
Portengen, Henk
Look, Maxime P.
Klijn, Jan G. M.
Lesche, Ralf
Schmitt, Manfred
Maier, Sabine
Foekens, John A.
Martens, John W. M.
BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (03) : 429 - 437
[44] Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
Kelly, Catherine Margaret
Crown, John
Russell, Niamh
Barron, Stephen
Lynch, Seodhna
O'Grady, Anthony
Sheehan, Katherine
Fay, Joanna
Amberger-Murphy, Verena
Saha, Anurati
Loughman, Tony
Dynoodt, Peter
Fender, Bozena
Ruiz, Cesar Lopez
Wang, Chan-Ju Angel
O'Leary, Desmond
O'Connor, Darran
Gallagher, William M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] CHEMOTHERAPY VERSUS TAMOXIFEN VERSUS CHEMOTHERAPY PLUS TAMOXIFEN IN NODE-POSITIVE, ESTROGEN RECEPTOR-POSITIVE BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC ITALIAN STUDY
BOCCARDO, F
RUBAGOTTI, A
BRUZZI, P
CAPPELLINI, M
ISOLA, G
NENCI, I
PIFFANELLI, A
SCANNI, A
SISMONDI, P
SANTI, L
GENTA, F
SACCANI, F
SASSI, M
MALACARNE, P
DONATI, D
FARRIS, A
CASTAGNETTA, L
DICARLO, A
TRAINA, A
GALLETTO, L
SMERIERI, F
BUZZI, F
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) : 1310 - 1320
[46] Weight Gain after Hormone Receptor-Positive Breast Cancer
Goyal, Archita
Milner, Gabrielle E.
Cimino-Mathews, Ashley
Visvanathan, Kala
Wolff, Antonio C.
Sharma, Dipali
Sheng, Jennifer Y.
CURRENT ONCOLOGY, 2022, 29 (06) : 4090 - 4103
[47] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
Rizki, Hirah
Hillyar, Christopher
Abbassi, Omar
Miles-Dua, Sascha
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
[48] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
Niu, Nan
Xue, Jinqi
Qiu, Fang
Chen, Guanglei
Gu, Xi
He, Guijin
Cao, Shuo
Yu, Xiaopeng
Xu, Yongqing
Yin, Jianqiao
Han, Sijia
Han, Ye
Tang, Meiyue
Zhao, Yafei
Zheng, Ran
Zheng, Xinyu
Xu, Hong
Liu, Caigang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Adjuvant chemotherapy in the node-negative breast cancer patient
Styblo, TM
Wood, WC
SURGICAL CLINICS OF NORTH AMERICA, 1996, 76 (02) : 327 - &
[50] ADJUVANT CHEMOTHERAPY FOR NODE-NEGATIVE BREAST-CANCER
SLEDGE, GW
MCCASKILLSTEVENS, W
CANCER INVESTIGATION, 1992, 10 (06) : 595 - 602

← 1 2 3 4 5 →